COGNICURRENT

Feb 2 • 18:12 UTC • 🇧🇷 Brazil • G1 (PT)

Anvisa approves the use of semaglutide for reducing cardiovascular risk

Brazil's National Health Surveillance Agency (Anvisa) has approved semaglutide for reducing the risk of cardiovascular events, a drug popularized for weight loss efficacy.

#semaglutide #cardiovascular #anvisa #brazil #weight loss

Read Original Back to Feed

📡 Similar Coverage

🇧🇷 Brazil Mar 21 • 03:01 UTC

Anvisa analyzes eight medications with semaglutide; see what changes with the patent expiration

G1 (PT)

🇧🇷 Brazil Feb 2 • 21:33 UTC

Anvisa approves indication of Ozempic and Wegovy to reduce the risk of heart attack and stroke

Folha (PT)

🇧🇷 Brazil Feb 18 • 11:15 UTC

Anvisa is set to decide next week on national versions of Ozempic

G1 (PT)

🇧🇷 Brazil Mar 21 • 06:14 UTC

Wegovy HD: higher dose of semaglutide approved by US agency to treat obesity

G1 (PT)

🇧🇷 Brazil Feb 15 • 07:00 UTC

Anvisa says it will comment in the coming weeks on the registration of two competitors to Ozempic

Folha (PT)

🇪🇸 Spain Feb 3 • 05:00 UTC

The 'miracle pill' against obesity achieves a new victory: it protects the heart

ABC